Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-09-07
Recursion Pharmaceuticals, Inc.
Clinical-stage biotechnology company using proprietary data, automated labs, and AI to discover and develop drugs internally and with pharma partners.
ai automation biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical Proof Is the Real Re-Rate Lever
This is an AI-enabled biotech with real proprietary inputs, but the upside depends on turning platform output into repeatable human proof. One lead rare-disease win plus a second internal validation could shift the market view from outsourced discovery story to emerging medicine engine.

Analysis

Thesis
Recursion is a leveraged bet that proprietary data, automated labs, and AI can become a repeatable medicine engine; if REC-4881 wins a credible approval path and one more internal asset shows human proof, the company can shift from lumpy collaboration revenue toward a multi-asset biotech with better downstream economics by 2031.
Last Economy Alignment
Cheaper cognition helps Recursion because better models can be reused across its owned data and lab system, but shareholder value still depends on turning platform output into real clinical proof.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.0x (from 5 most recent analyses)
Reasoning
The upside is a mix-shift story more than a pure AI story. A credible path for the lead rare-disease asset, one additional internally derived clinical proof point, and deeper partner economics can move the business from discovery-fee dependence toward product, milestone, and royalty revenue. That supports meaningful rerating, but not a perfection premium, because regulatory proof and financing still matter.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is proof conversion, not AI output volume. REC-4881 needs an approval-oriented path, at least one more internal asset needs credible human validation, and the company likely needs more capital before self-funding. If those gates slip, collaboration economics can stay lumpy, platform differentiation can look negotiable, and dilution can consume much of the operating progress.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.48
They control a hard-to-copy data factory and automated labs, so every improvement in AI can be reused across many drug programs and partnerships. The risk is simple: smarter models do not matter to shareholders unless they turn into real clinical wins before cash and time run short.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.22
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case